Isolation, expansion, transduction, and production of endothelial-cord derived working cell bank and blood stem cell transplantation final product in support of phase I-III clinical trials in malignancy
A new cell therapy manufacturing methodology needed to be tech transferred to Excellos manufacturing teams in a relatively short timeline as part of initiation of Phase I and Phase II clinical trials with the product.
Adverse Impact of NH₄Cl-Based Erythroreduction on T Cells
Standard NH₄Cl erythroreduction protocols significantly impair T cell metabolic fitness and phosphorylation (30-40% reduction) despite normal viability metrics, revealing critical blind spots in current cell therapy quality control.
T Cell Memory Variability in Healthy Allogeneic Donors
Tn/scm memory content varies dramatically across healthy donors and decreases non-linearly with age, while standard expansion protocols further reduce these critical cells essential for durable therapeutic responses.
CMC Consultation Services for Cell Therapy
Developers
Excellos offers free 60-minute CMC strategy consultations for early-stage cell therapy developers, addressing critical regulatory and manufacturing decisions before they become costly bottlenecks in IND filings and clinical timelines.d
Smart Selection of Leukapheresis Starting Material and
Continuous Process Improvement for iPBMC Manufacturing
Tumor-infiltrating leukocytes (TILs) are a promising autologous immunotherapeutic due to priorantigenic stimulation and ability to navigate tumor microenvironment (TMEs).